Leede Financial Weighs in on TSE:CPH FY2027 Earnings

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Research analysts at Leede Financial issued their FY2027 EPS estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial analyst D. Loe forecasts that the company will earn $1.10 per share for the year. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share.

Cipher Pharmaceuticals Stock Performance

TSE:CPH opened at C$12.65 on Monday. Cipher Pharmaceuticals has a 1-year low of C$7.90 and a 1-year high of C$19.69. The stock has a market cap of C$227.11 million, a P/E ratio of 13.97 and a beta of 1.20. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. The firm has a 50-day moving average of C$12.88 and a two-hundred day moving average of C$14.42.

Insiders Place Their Bets

In related news, Director Harold Morton Wolkin sold 3,500 shares of the business’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is owned by company insiders.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.